Need Help?

Assessment of genomic copy number alterations in breast cancer

The aim of this study was to assess genomic copy number alterations in a panel of breast cancer cell lines. These data were used to identify common aberrations associated with breast cancer, and also to identify aberrations associated with response to therapeutic compounds.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00000000119 Affymetrix 6.0 51
Publications Citations
Subtype and pathway specific responses to anticancer compounds in breast cancer.
Proc Natl Acad Sci U S A 109: 2012 2724-2729
300
HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression.
Springerplus 2: 2013 386
16
Modeling precision treatment of breast cancer.
Genome Biol 14: 2013 R110
181
A community effort to assess and improve drug sensitivity prediction algorithms.
Nat Biotechnol 32: 2014 1202-1212
361
Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers.
Nat Commun 7: 2016 12991
38
Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Nat Commun 8: 2017 1126
31
More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screens.
Pharmacol Ther 191: 2018 178-189
21